Enzalutamide is an oral prescription androgen-receptor inhibitor used to treat certain forms of prostate cancer. It interferes with androgen signaling that can support prostate-cancer growth.

The supplied product information identifies Enzamide 40 mg as a product containing enzalutamide, with Everest listed as the company.

Enzalutamide is used in specific prostate-cancer treatment settings, including selected hormone-sensitive and castration-resistant disease. Exact approved indications depend on the regulatory jurisdiction.

Enzalutamide is generally classified as targeted hormonal therapy rather than conventional cytotoxic chemotherapy. It works by blocking androgen-receptor signaling.

Enzalutamide inhibits androgen-receptor signaling. It interferes with androgen binding and receptor activity, reducing androgen-driven gene signaling in prostate-cancer cells.

The supplied website information identifies Enzamide in a 40 mg strength.

Current EMA product information for Xtandi includes 40 mg and 80 mg tablets.

Reference product information describes once-daily oral administration.

The current European reference product information recommends 160 mg once daily. This should not be treated as an individualized prescription.

Reference product information permits administration with or without food. Patients should follow the instructions for their specific product.

Patients should follow the missed-dose instructions in their applicable product information or contact their healthcare professional. They should not take extra medicine without professional advice.

Reported adverse effects can include fatigue, hot flushes, hypertension, headache, dizziness and other treatment-related effects. The exact frequency varies according to the clinical setting.

Yes. Seizures are an important identified risk. Patients with a history or increased risk of seizures should discuss this with their healthcare professional.

Ischemic heart disease is an important safety consideration associated with enzalutamide. Cardiovascular history should be discussed before treatment.

Yes. Enzalutamide can affect drug-metabolizing enzymes and can significantly alter the exposure of certain other medicines. A complete medication review is important.

No. Patients should not stop prescribed cancer treatment independently. Treatment changes should be discussed with the treating physician.

Dose changes should only be made by a qualified healthcare professional based on the patient's clinical circumstances and applicable product information.

The prescribing healthcare professional should know about significant medical conditions, particularly neurological and cardiovascular conditions, and all medicines and supplements being used.

No. Enzalutamide has specific indications and is not appropriate for every patient or every stage of prostate cancer.

Yes, depending on the indication. For example, current EMA information describes its use with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer.

Storage requirements should be taken from the official product labeling supplied with the specific medicine.

Check the product name, active ingredient, strength, packaging, manufacturer, batch or lot information and expiry date. When authenticity is uncertain, consult a pharmacist or authorized medicine source.

Both names refer to products containing enzalutamide only if their respective product labeling confirms this. A different brand should not automatically be represented as identical to Xtandi in every respect.

Treatment should be prescribed and supervised by an appropriately qualified healthcare professional experienced in prostate-cancer treatment.